 |
 |
I have obtained a copy of the Nature article that prompted this report. On reading it, there are a couple of things that are worthy of emphasis. First, this was a study in mice, not humans. Second, the article offers no explanation as to why isradipine (marketed as Dynacirc, as well as in generic formulations) was chosen, in preference to other calcium-channel blockers. The hypothesis is interesting and worthy of additional study, but seems to be far from a PD cure. Tony DeCamp Leesburg, VA ************************************** See what's free at http://www.aol.com. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn